Preprint
Article

This version is not peer-reviewed.

Use of the Zipf-Mandelbrot Law in Modelling US FDA Adverse Reactions

Submitted:

15 June 2026

Posted:

16 June 2026

You are already at the latest version

Abstract
Objective: The purpose of this preliminary study was to evaluate the use of the Zipf-Mandelbrot (ZM) law to mathematically model the percentage occurrence of adverse drug reactions (ADRs), as a function of rank, reported to the US FDA Adverse Event Monitoring System (AMES). Methods: Six commonly used hospital-based medications were examined. Nonlinear curve fitting of the two ZM coefficients was utilized to model the percentage occurrence of ADRs in a hierarchical or rank order for each drug examined. Results: The reported complications and their associated occurrence rates for all six medications were accurately modelled using the ZM law. Those medications which have a greater percentage of reported ADRs within their first ten ranks have a greater negative slope. Furthermore, a natural logarithmic transformation of both the reported FDA data and the predicted values utilizing the ZM law demonstrated a consistent statistically significant near-linear correlation. The ratio of the coefficients of the ZM law, a∙b-1, was also found to be a potentially useful index which allows for describing and comparing the overall shape of the medication-specific distributions. Conclusions: Based upon this preliminary examination, the ZM law appears to be applicable to the mathematical modeling of US FDA reported ADRs. Additional research to assess and utilize this law for the analysis, economic management, and possible improvement in patient outcome may be warranted.
Keywords: 
;  ;  
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2026 MDPI (Basel, Switzerland) unless otherwise stated